董事會召開日期 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 上海心瑋醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此 宣佈，本公司將於2026年3月26日（星期四）舉行董事會會議，藉以（其中包括） 審議及批准本公司及其附屬公司截至2025年12月31日止年度之全年業績及其發 佈，以及考慮建議派付末期股息（如有）。 承董事會命 上海心瑋醫療科技股份有限公司 董事長 王國輝 上海，2026年3月16日 於本公告日期，執行董事為王國輝先生、張坤女士及韋家威先生；非執行董事為丁魁先生、 陳少雄先生及陳剛先生；及獨立非執行董事為郭少牧先生、馮向前先生及龔平先生 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry in China [6] Core Viewpoints - The report emphasizes that semi-invasive brain-machine interfaces (BMIs) demonstrate significant safety advantages over invasive methods, making them more suitable for consumer applications [9][10] - The potential for semi-invasive BMIs to address safety concerns during implantation, long-term use, and removal is highlighted, suggesting a greater development potential [9][10] - The report identifies that the market for BMIs is expected to grow significantly, particularly in the treatment of neurological diseases, which will pave the way for future consumer-level applications [19][21] Summary by Sections 1. Semi-Invasive Surgery: Smaller Incisions and Shallow Implantation - Semi-invasive techniques are less invasive, reducing surgical risks compared to invasive methods [9][10] - The report notes that semi-invasive BMIs can achieve shallower implantation depths, minimizing damage to brain tissue [9][10] - The potential for algorithm advancements to further enhance implantation techniques is discussed [49] 2. Long-Term Safety and Higher Channel Limits - Semi-invasive BMIs do not form scar tissue, maintaining neuron integrity, which is crucial for long-term stability [51][57] - The report indicates that semi-invasive designs can avoid electrode displacement, which is a significant risk in invasive methods [61][67] - The ability of semi-invasive BMIs to manage thermal limits effectively is emphasized, allowing for higher channel counts without compromising safety [69][73] 3. Safer Removal and Greater Consumer Potential - The report highlights that removing semi-invasive electrodes poses less risk of damaging blood vessels compared to invasive electrodes [11][14] - The increasing frequency of hardware upgrades in BMIs necessitates safer removal methods, which semi-invasive designs can provide [11][14] - The report suggests that as the market for BMIs expands, semi-invasive methods will better meet consumer demands for easy replacement and upgrades [11][14] 4. Investment Recommendations and Targets - The report recommends focusing on semi-invasive BMI solutions with clear clinical progress and government support [14] - It suggests exploring companies within the semi-invasive BMI supply chain that show potential breakthroughs in the medical field and can extend into consumer markets [14]

Group 1: Pharmaceutical and Biotechnology Sector - Four Seasons Pharmaceutical (00460) saw a stock increase of 3.7% after receiving approval from the NMPA for its innovative drug, Pyrocilin Tablets, for treating HR+/HER2- advanced breast cancer [1] - Hengrui Medicine (01276) rose over 5% following the approval of a clinical trial for HRS-1780 Tablets aimed at treating primary hyperaldosteronism [3] - Mirxes-B (02629) experienced a stock surge of 10.86% after announcing a strategic partnership with Apollo Health to develop advanced cancer early detection solutions in India [3] - Cornerstone Pharmaceuticals-B (02616) increased by 12.37% after receiving FDA approval for its IND application for CS2009, a tri-specific antibody for advanced solid tumors [4] - Deciphera Pharmaceuticals-B (06996) rose 16.77% after signing an agreement with U.S. Biotech for the global development and commercialization of ATG-201, a dual-specific T-cell engager [5] Group 2: Automotive Sector - Automotive stocks showed a collective rebound, with XPeng Motors-W (09868) up 3.14% and NIO-SW (09866) up 3.43%, driven by news of BYD's upcoming launch of its second-generation blade battery and fast-charging technology [2] Group 3: Technology and Communication Sector - Optical communication stocks rallied, with Cambridge Technology (06166) up 8.7% after NVIDIA announced a $40 billion investment in optical technology through partnerships with Lumentum and Coherent [1] - Brain-computer interface stocks surged, with Nanjing Panda Electronics (00553) increasing by 24.64% following government reports emphasizing the development of future industries, including brain-computer interfaces [2] Group 4: Cryptocurrency Sector - Cryptocurrency-related stocks rebounded, with Okex Cloud Chain (01499) rising 15.89% as Bitcoin surpassed $72,000, driven by short-covering amid geopolitical concerns [5][6]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 31,565,804 | RMB | | 1 RMB | | 31,565,804 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 31,565,804 | RMB | | 1 RMB | | 31,565,804 | | 2. 股份分類 | ...

Company Performance Goals - The company announced a revenue target of no less than 540 million yuan and a profit target of no less than 100 million yuan for the year 2026, demonstrating confidence in performance growth [1] Product Development Progress - The self-expanding intracranial drug-eluting stent's registration application was accepted by the National Medical Products Administration in January 2026, with certification expected by the end of 2026, potentially becoming the world's first product of its kind [2] - Products such as the spring coil are expected to receive overseas market certification in the first quarter of 2026, accelerating international expansion [2] Business Development Status - The interventional brain-computer interface project has completed technical validation, with the first human clinical trial expected to start in 2026 and a registration application planned for 2028, laying the foundation for innovation breakthroughs in the field of neuromodulation [3] Strategic Advancement - The company plans to apply for listing on the Sci-Tech Innovation Board in 2026 based on 2025 financial data and is currently in the listing guidance phase, which, if successful, will enhance the liquidity of its capital platform [4]

Group 1 - The core viewpoint of the article highlights that Xinyi Medical achieved a turnaround in 2025, reporting a revenue exceeding 400 million yuan and setting a 2026 target of at least 540 million yuan in revenue and 100 million yuan in profit, indicating confidence in growth prospects [1] Group 2 - In the recent stock performance, Xinyi Medical's B-share price showed volatility over the past week, with a 5-day change of -0.57%, and the latest stock price at 48.50 HKD. The trading volume during this period was approximately 4.57 million HKD, with technical indicators suggesting short-term adjustment pressure [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 31,565,804 | RMB | | 1 RMB | | 31,565,804 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 31,565,804 | RMB | | 1 RMB | | 31,565,804 | | 2. 股份分類 | ...

上海心瑋醫療科技股份有限公司 章 程 （於2026年1月16日的臨時股東大會審閱通過） | 第一章 | 總則 | 1 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 3 | | 第三章 | 股份 | 4 | | 第一節 | 股份發行 | 4 | | 第二節 | 股份增減和回購 | 9 | | 第三節 | 股份轉讓 | 13 | | 第四節 | 購買公司股份的財務資助 | 14 | | 第五節 | 股票和股東名冊 | 16 | | 第四章 | 股東和股東會 | 20 | | 第一節 | 股東 | 20 | | 第二節 | 股東會的一般規定 | 26 | | 第三節 | 股東會的召集 | 28 | | 第四節 | 股東會的提案與通知 | 30 | | 第五節 | 股東會的召開 | 33 | | 第六節 | 股東會的表決和決議 | 38 | | 第七節 | 類別股東表決的特別程序 | 43 | | 第五章 | 董事會 | 46 | | 第一節 | 董事 | 46 | | 第二節 | 董事會 | 49 | | 第三節 | 董事會專門委員會 | 54 | | 第六章 | 高級管理人員 | ...

Group 1 - The article reports on share buybacks conducted by various companies on January 23, 2026, with a total of 36 companies participating in the buyback program [1] - The largest buyback amount was by Sunny Optical Technology (02382), which repurchased 850,000 shares for a total of 54.15 million yuan [1] - Other notable buybacks include China Resources Gas (01193) with 1.05 million shares repurchased for 22.80 million yuan and Country Garden Services (06098) with 2.10 million shares for 13.17 million yuan [1] Group 2 - The cumulative buyback numbers for the year show that Sunny Optical Technology has repurchased a total of 12.72 million shares, representing 1.162% of its total share capital [2] - China Resources Gas has repurchased 404.44 million shares, accounting for 0.175% of its total share capital [2] - Kuaishou-W (01024) repurchased 1.24 million shares, which is 0.450% of its total share capital [2] Group 3 - Other companies with significant buybacks include Yum China (09987), which repurchased 20,100 shares for 7.69 million yuan, representing 5.220% of its total share capital [2] - The buyback activity reflects a trend among companies to return capital to shareholders amid market conditions [1][2] - The data indicates a diverse range of industries participating in the buyback program, from technology to healthcare and consumer services [1][3]

Group 1 - The company, 心玮医疗-B (06609), announced a share buyback plan [1] - The company will spend HKD 2.2582 million to repurchase 40,000 shares [1] - The buyback is scheduled for January 23, 2026 [1]